Iżrael - Ebrajk - Ministry of Health

rafa laboratories ltd - bosentan as monohydrate - טבליה - bosentan as monohydrate 62.5 mg - bosentan

Iżrael - Ebrajk - Ministry of Health

genmedix - tamsulosin hydrochloride 0.4 mg - modified release capsules - tamsulosin - treatment of functional symptoms of benign prostatic hyperplasia (bph).

Iżrael - Ebrajk - Ministry of Health

mediline ltd. - minoxidil 2 % - solution - minoxidil - androgenetic alopecia in males and females.

Iżrael - Ebrajk - Ministry of Health

דיאסורין בע"מ - אחר - בתחומי אימונולוגינה ומיקרוביולוגיה in vitro ביצוע בדיקות אבחוניות

Iżrael - Ebrajk - Ministry of Health

medtronic - רופא - משתלים ביולוגיים אוטופדיים

Iżrael - Ebrajk - Ministry of Health

דיאסורין בע"מ - אחר - בתחומי אימונולוגינה ומיקרוביולוגיה in vitro ביצוע בדיקות אבחוניות

Iżrael - Ebrajk - Ministry of Health

astrazeneca (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - ספריי לאף - b/phuket/3073/2013 (b/yamagata lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/darwin/9/2021 (h3n2)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 7 ±0.5 log10 ffu^a / 0.2 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 7 ±0.5 log10 ffu^a / 0.2 ml - influenza, inactivated, split virus or surface antigen - influenza, purified antigen - flumist quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses ad type b viruses contained in the vaccine. flumist quadrivalent is approved for use in persons 2 through 49 years of age.

Iżrael - Ebrajk - Ministry of Health

ג'י.אן.אי אופק בעמ - לחות לפנים

Iżrael - Ebrajk - Ministry of Health

neopharm scientific ltd - lenalidomide 5 mg - capsules - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Iżrael - Ebrajk - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.